Eltrekibart: Primaty completion of P2 trial (NCT06046729) adult participants with moderate to severe hidradenitis suppurativa in Aug 2025 (Eli Lilly) - Aug 8, 2024 - Q2 2024 Results: Completion of P2 trial (NCT06046729) adult participants with moderate to severe hidradenitis suppurativa in Jul 2026
Trial completion date • Trial primary completion date • Hidradenitis Suppurativa
|